Literature DB >> 30652093

Gut microbiome: a key player in cancer immunotherapy.

Yasuyuki Shigematsu1, Kentaro Inamura1.   

Abstract

Entities:  

Year:  2018        PMID： 30652093      PMCID： PMC6295395          DOI： 10.21037/hbsn.2018.10.02

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  5 in total

1.  The impact of microbiome in urological diseases: a systematic review.

Authors:  Joseph K M Li; Peter K F Chiu; Chi-Fai Ng
Journal:  Int Urol Nephrol       Date:  2019-07-12       Impact factor: 2.370

2.  Potential factors of specialists' willingness to write editorial and commentary: a retrospective study based on 5,091 invitations.

Authors:  Hengrui Liang; Lujiao Ye; Wenhua Liang; Runchen Wang; Fan Ge; Lihua Fan; Yao Zhu; Grace S Li; Stephen D Wang; Kevin Phan; Alan Sihoe; Kaiping Zhang; Jianxing He
Journal:  Ann Transl Med       Date:  2019-12

Review 3.  Intestinal microbiota: a new force in cancer immunotherapy.

Authors:  Zhujiang Dai; Jingqiu Zhang; Qi Wu; Huiwen Fang; Chunfeng Shi; Zhen Li; Chaobiao Lin; Dong Tang; Daorong Wang
Journal:  Cell Commun Signal       Date:  2020-06-10       Impact factor: 5.712

Review 4.  The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy.

Authors:  Aneta Sevcikova; Nikola Izoldova; Viola Stevurkova; Barbora Kasperova; Michal Chovanec; Sona Ciernikova; Michal Mego
Journal:  Int J Mol Sci       Date:  2022-01-01       Impact factor: 5.923

5.  Breath methane to hydrogen ratio as a surrogate marker of intestinal dysbiosis in head and neck cancer.

Authors:  Nuwan Dharmawardana; Thomas Goddard; Charmaine Woods; David I Watson; Ross Butler; Eng H Ooi; Roger Yazbeck
Journal:  Sci Rep       Date:  2020-09-14       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.